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Abstract 
Background and Objective: The role of peptidases in carcinogenic processes and their po-
tential usefulness as tumor markers in colorectal cancer (CRC) have been classically attributed to 
cell-surface enzymes. The objective of the present study was to analyze the activity and mRNA 
expression of three cytosolic peptidases in the CRC and to correlate the obtained results with 
classic histopathological parameters for tumor prognosis and survival. 
Methods: The activity and mRNA levels of puromycin-sensitive aminopeptidase (PSA), ami-
nopeptidase B (APB) and pyroglutamyl-peptidase I (PGI) were measured by fluorimetric and 
quantitative RT-PCR methods in colorectal mucosa and tumor tissues and plasma samples from 
CRC patients (n=81).  
Results: 1) PSA and APB activity was higher in adenomas and carcinomas than in the uninvolved 
mucosa. 2) mRNA levels of PSA and PGI was lower in tumors. 3) PGI activity in CRC tissue 
correlated negatively with histological grade, tumor size and 5-year overall suvival of CRC patients. 
4) Higher plasmatic APB activity was independently associated with better 5-year overall survival.  
Conclusions: Data suggest that cytosolic peptidases may be involved in colorectal carcinogenesis 
and point to the determination of this enzymes as a valuable method in the determination of CRC 
prognosis. 
Key words: colorectal cancer, prognosis, survival, cytosolic, soluble, peptidases. 
Introduction 
Colorectal cancer (CRC) is the second common-
est malignancy in males and females in Europe [1] 
and the third in the United States [2]. Huge resources 
are being invested in prevention and early diagnosis 
of this disease. Population-based screening campaigns 
try to discover as much early tumors and precursor 
lesions as possible, aiming to decrease the incidence of 
the disease, to simplify the clinical management of 
patients once the lesion develops, and to improve 
survival [3]. However, despite of the advances in 
screening, surgery and radio and chemotherapy, it is 
still the second cause of cancer deaths in the devel-
oped countries [4]. 
The molecular classification of CRC proposed by 
Jass in 2007 [5] has been of much help in the under-
standing of the diverse etiopathogenetic mechanisms 
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of this disease. From a pathological perspective, ade-
nomatous lesions in the large bowel are fully accepted 
precursors of CRC and the adenoma-carcinoma se-
quence still provides a solid model for research on 
carcinogenesis [4,6]. These adenomatous polyps and 
subsequent carcinoma appear to develop with se-
quential genetic alterations which affect to the ex-
pression of several proteins, such as peptidases [7,8].  
Peptidases play a key role in cell proliferation, 
angiogenesis and tumor invasiveness by regulating 
extracellular matrix degradation and cell signalling 
and recognition [8,9]. The expression and activity of 
these enzymes vary in cancer depending on the sev-
eral clinicopathological parameters like histological 
grade, stage, and patient survival [8-11]. For this rea-
son, peptidases are useful tools in the development of 
clinical strategies for treatment and follow up of can-
cer patients. 
Although the role of these proteins in carcino-
genic processes and their potential usefulness as tu-
mor markers in CRC was initially proposed for 
cell-surface enzymes [8,12,13], it has been demon-
strated that cytosolic peptidases also participate in 
several hallmarks of cancer [14-19]. In addition, it has 
been reported that the activity of different cytosolic 
peptidases such as puromycin-sensitive aminopepti-
dase (PSA or EC 3.4.11.14), aminopeptidase B (APB or 
EC 3.4.11.6) and pyroglutamyl-peptidase I (PGI or EC 
3.4.19.3) was altered in breast [19,20], kidney [21,22] 
and thyroid tumors [23]. 
Regarding CRC, recently we demonstrated that 
the activity and mRNA expression of prolyl endo-
peptidase (PEP) and aspartyl aminopeptidase (ASP), 
was altered throughout the uninvolved colorectal 
mucosa-adenoma-carcinoma sequence. Moreover, 
tissue and plasmatic activity of both enzymes was 
correlated with tumor invasiveness and 5-year sur-
vival of CRC patients [16-18]. All these evidences 
point to the analysis of cytosolic peptidases as a 
promising tool in the design of new diagnos-
tic/prognostic biomarkers in CRC.  
In this context, the objective of the present work 
was to study the activity and mRNA expression of 
PSA, APB and PGI in the adenoma-adenocarcinoma 
sequence and plasma samples from patients with 
CRC, and to correlate the obtained results with classic 
histopathological parameters for tumor prognosis and 
survival. 
Materials & Methods 
 The authors declare that all the experiments 
carried out in this study comply with current Spanish 
laws and conform to the principles outlined in the 
Declaration of Helsinki.  
Patients 
 81 patients with CRC were prospectively in-
cluded in the study. Males predominated in the series 
(51M/30F), the average age being 70.1 years for males 
and 67 years for females. Mean follow-up was 50.2 
months (range 3-80). All patients received partial co-
lectomies. In 16 of these patients, both adenomatous 
polyps and adenocarcinomas were diagnosed. These 
cases were used to analyze peptidase activity and 
mRNA levels throughout the uninvolved muco-
sa-adenoma-adenocarcinoma sequence.  
Follow-up was closed by December 31, 2012. At 
that time, 25 patients had died of disease. AJCC sys-
tem [24] has been applied to assign Stage and Grade. 
Clinical data included in the study were retrieved 
from the patient clinical records and are summarized 
in Table 1A. Plasma was also collected preoperatively 
and analyzed in 40 of these patients. Table 1B shows 
the clinicopathological data in this subset of patients. 
Plasma from 28 healthy volunteers with no clinical 
history of neoplastic diseases was used as control 
sample.  
Tissue Specimens 
Surgical resections were submitted in fresh to the 
Pathology Lab within a period of 30 minutes after 
removal. Handling of specimens was performed fol-
lowing conventional protocols for the management of 
surgical resections of colon and rectum [25]. Tumor 
characteristics were recognized on gross examination 
and selected fragments of tumor were frozen in iso-
pentane and stored at -80ºC. Besides, peripheral ve-
nous blood samples from 40 of these patients were 
collected prior to surgery in EDTA tubes and centri-
fuged at 1500 rpm during 15 minutes. The obtained 
plasma was also stored at -80ºC. Enzyme assays have 
also been performed in plasma obtained from 28 
healthy volunteers (matched by sex and age). 
Sample preparation 
Explanted tumor and non-tumor samples were 
homogenized in 10 mM Tris-HCl buffer at pH 7.4, 
using a Heidolph PZR 50 Selecta homogenizer, and 
ultracentrifuged in a Centrikon T-2070 Kontron In-
struments apparatus at 100,000g for 35 minutes. The 
resulting supernatants (soluble fractions) were used 
to measure PGI, APB and PSA activity [19,26]. Previ-
ously collected plasma samples were used to deter-
mine plasmatic PGI, APB and PSA activity. All the 
above-described steps were carried out at 4 °C.  
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Table 1A. Peptidase activity in CRC tissue according to clinicopathological characteristics. Values are means ± SE of pep-
tidase activity recorded as pmol of units of peptidase (UP) per milligram of protein. 
Variables  n = APB PSA PGI 
UP/mg prot 
(Mean ± S.E ) 
Mann-Whitney 
(p =) 
UP/mg prot 
(Mean ± S.E ) 
Mann-Whitney 
(p =) 
UP/mg prot 
(Mean ± S.E ) 
Mann-Whitney 
(p =) 
Grade         
Low (G1-G2) 64 13946 ± 1104 0.101 15570 ± 1164 0.385 186.84 ± 28.12 0.011 
High (G3-G4)  17 12591 ± 4562 13058 ± 2994 126.25 ± 5.89 
Stage         
Low (T1-T2)  11 11474 ± 2471 0.847 13894 ± 2418 0.916 152.2 ±55.52 0.606 
High (T3-T4)  70 14235 ± 1229  15501 ± 1214 183.96 ± 27.64 
Nodal invasion         
No 50 13429 ± 1371 0.625 14510 ± 1316 0.839 164.6 ± 18.09 0.820 
Yes  31 14493 ± 1920 16810 ± 1865 209.33 ± 69.79 
Distant Metastases         
No  74 13757 ± 1177 0.589 14797 ± 1105 0.349 185.31 ± 26.72 0.183 
Yes  7 13776 ± 3797 18917 ± 4143 119.33 ± 44.22 
Lymphatic invasion         
No 72 13606 ± 1179 0.333 15118 ± 1144 0.548 188.44 ± 27.74 0.050 
Yes  9 14714 ± 3517 15884 ± 3580 116.25 ± 25.7 
Vascular invasion         
No 66 14479 ± 1166 0.161 15379 ± 1082 0.705 192.04 ± 29.9 0.429 
Yes  15 11000 ± 2838 14629 ± 3401 126.5 ± 22.11 
Perineural invasion         
No 77 13677 ± 1139 0.861 15120 ± 1111 0.846 180.21 ± 25.33 0.949 
Yes  4 12948 ± 2542 15584 ± 2019 154 ± 24.4 
Grouped stage         
Low (0-IIC) 46 13505 ± 1443 1.000 14332 ± 1375 0.542 162.84 ± 18.98 0.758 
High (IIIA-IV)  35 14242 ± 1735 16918 ± 1671 208.2 ± 62.44 
Topographic distribution        
Colon  14064 ± 828 0.023 16108 ± 724 0.044 195 ± 18 0.026 
Rectum  10580 ± 1162  13009 ± 1142 130 ± 15 
 
 
Table 1B. Peptidase activity in plasma from CRC patients according to clinicopathological characteristics. Values are 
means ± SE of units of peptidase per liter of plasma (UP/L). 
Variables  n = APB PSA PGI 
UP/L  
(Mean ± S.E ) 
Mann-Whitney 
(p =) 
UP/L 
(Mean ± S.E ) 
Mann-Whitney 
(p =) 
UP/L  
(Mean ± S.E ) 
Mann-Whitney 
(p =) 
Grade         
Low (G1-G2) 33 100.16 ± 7.63 0.364 395.80 ± 38.71  0.064 25.24 ± 4.23 0.242 
High (G3-G4)  7 88.75 ± 19.23  253.25 ± 43.82  8.49 ± 0.91  
Stage         
Low (T1-T2)  9 100.6 ± 24.84 0.915 360 ± 113 1.000 9.27 ± 1.37 0.421 
High (T3-T4)  31 98.17 ± 7.05  379.5 ± 36.5 25.77 ± 4.38 
Nodal invasion         
No 29 98.9 ± 7.16 0.802 380.35 ± 45.65 0.918 29.74 ± 4.79 0.073 
Yes  11 97.89 ± 16.8 366.78 ± 52.56 7.78 ± 0.65 
Distant Metastases         
No  37 97.23 ± 6.6 0.959 378.81 ± 38.22 0.700 23.57 ± 4.09 0.330 
Yes  3 110.33 ± 42.99 353 ± 82.6 17.39 ± 11.14 
Lymphatic invasion         
No 34 95.8 ± 6.7 0.519 373 ± 39.42 1.000 25.39 ± 4.21 0.068 
Yes  6 116 ± 30.92 395.75 ± 69.66 7.56 ± 1.31 
Vascular invasion         
No 33 101.96 ± 7.94 0.669 396.56 ± 41.03 0.557 23.49 ± 4.51 0.522 
Yes  7 85.67 ± 14.91 297.83 ± 56.03 20.77 ± 6.83 
Perineural invasion         
No 38 98.93 ± 7.25 0.862 380.32 ± 35.97 0.829 22.26 ± 3.88 0.328 
Yes  2 89 ± 6.1 259 ± 31.2 41.74 ± 8.23 
Grouped stage         
Low (0-IIC) 28 99.84 ± 7.48 0.740 388.47 ± 47.36 0.885 29.23 ± 5.02 0.136 
High (IIIA-IV)  12 96.2 ± 15.12 352.7 ± 49.07 10.96 ± 3.23 
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PGI, APB, PSA activity measurements 
 PGI, APB and PSA activity was fluorimetrically 
measured using a modified version of the method 
described by Zambotti-Villela et al. [27]. PGI was 
quantified with pGlu-β-naphthylamide (0.125mM) as 
substrate and APB with Arg-β-naphthylamide 
(0.125mM). In the case of PSA was measured using 
Ala-β-naphthylamide (0.125mM) as substrate. To dis-
criminate between PSA and aminopeptidase N forms 
of total alanine aminopeptidase activity, incubations 
with the speciﬁc PSA inhibitor puromycin (40µM) 
were performed in parallel.  
The assay is based on the fluorescence of 
β-naphthylamine generated from the hydrolysis of the 
substrate by the enzyme. The components of the as-
says mixtures (1 ml) included the following: PGI assay 
[(50mM of sodium phosphate buffer (pH 7.4), 2 mM of 
DL-dithiothreitol and 0.1mg/ml of bovine serum al-
bumin)]; APB assay [(50mM of sodium phosphate 
buffer (pH 7.4),150 mM NaCl, puromycin (40µM) and 
0.1mg/ml of bovine serum albumin, pH 6.5)]; PSA 
assay [(50mM of sodium phosphate buffer (pH 7.4), 
puromycin (40µM) and 0.1mg/ml of bovine serum 
albumin].  
The reaction was initiated by adding 30µL (APB 
and PSA) or 50µL (PGI) of tissue or plasma sample to 
1mL of the assay mixture. This was incubated at 37ºC 
for 30 minutes and the reaction was stopped by addi-
tion of 1 mL of 0.1M sodium acetate buffer (pH 4.2). 
The excitation and emission wavelengths were 345 
and 412 nm, respectively. Blanks were used to deter-
mine background fluorescence. Relative fluorescence 
was converted into picomoles of product using a 
standard curve constructed with increasing concen-
trations of β-naphthylamine.  
 Protein concentration was measured in triplicate 
by the Bradford method [28], using BSA (1 mg/mL) as 
calibrator. Results from the CRC tissues and from 
plasma samples were recorded as units of peptidase 
per milligram of protein (UP/mg prot) and per liter of 
plasma (UP/L), respectively. One unit of peptidase 
activity (UP) is the amount of enzyme required to 
release one pmol of β-naphthylamine per minute. 
Fluorogenic assays were linear with respect to hy-
drolysis time and protein content. 
Real-time quantitative PCR analysis 
Quantitative RT-PCR for detecting PGPEP1 
(PGI), RNPEP (APB) and NPEPPS (PSA) mRNA was 
performed to determine the transcription levels of 
these peptidases. The RNA of tumor and nontumor 
tissue samples from CRC patients was isolated with 
the RNeasy Protect kit (Qiagen), including a DNase 
digestion step using an RNase-free DNase kit (Qi-
agen) to exclude possible contamination by genomic 
DNA. First-strand cDNA was synthesized from 25 µg 
of total RNA from each human sample using Moloney 
murine leukemia virus reverse transcriptase and 
random hexamers according to the manufacturer’s 
instructions (first-strand cDNA Synthesis Kit, Amer-
sham Biosciences, Essex, UK). The resulting cDNA 
samples were amplified by PCR (7900 Real-Time PCR 
System, Applied Biosystems) with specific oligonu-
cleotide primer pairs designed with the analysis 
software Primer 3 and synthesized by Sigma-Genosys 
(Cambridge, UK).  
Based on previous experiments on CRC [17], 
human renal cell carcinoma [21] and other human 
tissues [29], TATA box binding protein (TBP), pepti-
dylprolyl isomerase A (PPIA), Hypoxantine phos-
phoribosyltransferase 1 (HPRT1), Polymer-
ase(RNA)II(DNA directed) polypeptide A (POLR2 A), 
Glyceraldehyde-3´´-phosphate dehydrogenase 
(GAPDH) and succinate dehydrogenase complex 
subunit A (SDHA) were chosen as endogenous ref-
erence genes. The sequences of the primers used to 
amplify PGI, APB, PSA and the six housekeeping 
genes are shown in Table 2. All primers were synthe-
sized and purified by Sigma-Genosys (Cambridge, 
UK). 
 
Table 2. Sequence of forward (F) and reverse primers (R) of indicated target genes and the size expected for each 
PCR-amplified product. Primers for the assayed housekeeping genes are also shown. 
Enzyme/HKG Gene Symbol Forward Primer Reverse Primer Amplicon 
size (bp) 
Piroglutamyl aminopeptidase PGPEP1 5´-GCCCTGTGGGAGAAGCAC-3´ 5´-AGCCCCTTGTAGCCCTTGTT-3´ 110 
Aminopeptidase B RNPEP 5´-CGAAGCATCTTAGCCGATGAC-3´ 5´-TCGATCAAACTCAAAACCTGGA-3´ 102 
Aminopeptidase puromycin sensitive NPEPPS 5´-CGTTAGAAGAAGCCCGTCGT-3´ 5´-AAAGTAGTGCCATCACCATGCTT-3´ 118 
TATA box binding protein TBP 5´-GGATAAGAGAGCCACGAACCAC-3´ 5´-TTAGCTGGAAAACCCAACTTCTG-3´ 139 
Succinate dehydrogenase complex, subunit A SDHA 5´-TCTGCCCACACCAGCACT-3´ 5´-CCTCTCCACGACATCCTTCC-3´ 142 
Peptidylpropyl isomerase A PPiA 5´-GGTCCCAAAGACAGCAGAAAA-3´ 5´-TCACCACCCTGACACATAAACC-3´ 114 
Hypoxantine phosphoribosyltransferase 1 HPRT1 5´-GCCAGACTTTGTTGGATTTGA-3´ 5´-GGCTTTGTATTTTGCTTTTCC-3´ 130 
Polymerase(RNA)II(DNA directed) polypep-
tide A 
POLR2A 5´-ACATCACTCGCCTCTTCTACTCC-3´ 5´-GTCTTGTCTCGGGCATCGT-3´ 268 
Glyceraldehyde-3´´-phosphate dehydrogenase GAPDH 5´-CAATGCCTCCTGCACCAC-3´ 5´-CCTGCTTCACCACCTTCTTG-3´ 350 
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Statistical analysis 
Kolmogorov-Smirnov and Shapiro-Wilk tests 
were applied to data obtained from tissue and plasma 
samples respectively to know if the numbers followed 
or not a normal distribution. Based on this infor-
mation (p<0.05), peptidase activities in tissue and 
plasma were analyzed with non parametric probes: 
Mann-Whitney test and Kruskal-Wallis tests were 
used to detect differences between two or three 
groups, respectively. Spearman`s correlation test was 
performed to evaluate the correlation between tissue 
and plasmatic activities and with tumor size and pa-
tients’ gender.  
 Finally, Kaplan-Meier curves and log-rank test 
were performed to evaluate the association between 
soluble peptidase activities and 5-year survival. The 
compared groups were created by cut-off points 
based on median enzyme activity values, as previ-
ously reported [30,31]. A Cox regression model was 
used to test the independent effects of clinical and 
pathological variables and peptidase activity on 
five-year overall survival. SPSS® 21.0 software was 
used for the statistical analysis. 
Results 
Peptidase activity and mRNA expression in 
tissue specimens  
APB and PSA peptidase activity was signifi-
cantly higher in tumor samples (adenoma and ade-
nocarcinoma) than in the adjacent non-tumor tissue 
(Kruskal-Wallis, p=0.001 for APB and p=0.0001 for 
PSA). In the adenomas the activity was near to three 
and two-fold higher than the uninvolved mucosa, 
respectively. PGI activity was higher in adenocarci-
nomas, however it did not reach statistical signifi-
cance (Kruskal-Wallis, p= 0.2). Results are summa-
rized in Table 3A.  
 Table 3A. Peptidase activity in tissue from CRC patients. 
Values are means + SE of peptidase activity recorded as pmol of 
units of peptidase (UP) per milligram of protein. a: Adenocarci-
noma vs Adenoma; b: Adenocarcinoma vs Normal; c: Adenoma vs 
Normal.  
Peptidase UP/L (Mean ± S.E) Mann- Whitney (p =) 
APB    
Adenocarcinoma 13298 ± 693 0.073a 
Adenoma 27812 ± 4202 0.002b 
Non-tumoral 10952 ± 1531  0.001c 
PSA    
Adenocarcinoma 15355 ± 621 0.443a 
Adenoma 19747 ± 2296 0.0001b 
Non-tumoral 10587 ± 880  0.001c 
PGI    
Adenocarcinoma 176 ± 14.35 0.145a 
Adenoma 138 ± 12.02 0.156b 
Non-tumoral 151 ± 18.38  0.934c 
 
These differences were not correlated with 
mRNA levels. Thus, PGPEP1 (PGI) and NPEPPS 
(PSA) were downregulated in tumor specimens 
compared with non-neoplasic tissue (Kruskal-Wallis, 
p<0.001 for both genes) and RNPEP (APB) mRNA 
levels were similar throughout the uninvolved mu-
cosa-adenoma-adenocarcinoma sequence (Table 3B). 
 
Table 3B. Peptidase mRNA expression. Values are means ± 
SE of peptidase mRNA expression recorded as relative units. a: 
Adenocarcinoma vs Adenoma; b: Adenocarcinoma vs Normal; c: 
Adenoma vs Normal.  
Peptidase  Relative Units (Mean ± S.E )  Mann-Whitney (p =)  
RNPEP (APB)    
Adenocarcinoma 163.93 ± 34.81 0.144a 
Adenoma 174.8 ± 15.76 0.797 b 
Non-tumoral 153.76 ± 26.03  0.312 c 
NPEPPS (PSA)    
Adenocarcinoma 107.89 ± 15.36 0.001a 
Adenoma 36.06 ± 6.2 0.029b 
Non-tumoral 166.29 ± 20.2  0.0001c 
PGPEP1 (PGI)    
Adenocarcinoma 43.15 ± 7.17 0.005a 
Adenoma 13.73 ± 2.12 0.001b 
Non-tumoral 157.07 ± 41.39  0.0001c 
 
Peptidase activity in CRC tissue according to 
clinicopathological variables and topographic 
distribution 
Adenocarcinomas with low grades showed 
higher PGI activity than high grade tumors 
(Mann-Whitney, p=0.011). A similar tendency was 
observed in CRCs showing lymphatic invasion, alt-
hough this result was not significant (Mann-Whitney, 
p=0.05). PSA and APB activities did not revealed sig-
nificant changes. These results are summarized in 
Table 1A.  
Topographic distribution of adenocarcinomas 
displayed significant differences in all the analyzed 
peptidases, with higher activities in adenocarcinomas 
located in the colon than in the rectum 
(Mann-Whitney, p<0.05 for all cases) (Table 1A). To 
elucidate if these significant differences between the 
two topographies, colon and rectum, were related 
with the chemo-radiotherapy regimes previously 
administered to some patients with rectal adenocar-
cinoma, we compared enzyme activities in cases with 
and without this previous treatment. However, it did 
not throw any significant result (Mann-Whitney, p > 
0.05 in all cases). 
We also analyzed if there is any correlation be-
tween tissue and plasmatic activities, and between 
tumor size and patients’ gender and enzyme activi-
ties. We only found a statistically significant correla-
tion between tissue PGI activity and tumor size 
(Spearman Rho test, r= -0.248, p= 0.04) (Figure 1). 
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Peptidase activity in tissue according to overall 
survival  
Kaplan-Meier curves and log-rank test showed 
that five-year overall survival (OS) of patients with 
CRC was better when PGI activity was higher than 
165 UP/mg of protein (log-rank p=0.002) (Figure 2A). 
A similar trend was observed with APB and PSA 
(cut-off value 15000 UP/mg for both enzyme activi-
ties), when five-year OS was analyzed by log-rank 
test, although it did not reach statistical significance 
(p=0.07 and p=0.057, respectively). 
Multivariate Cox regression model showed that 
PGI activity (p=0.04) and grouped stage (p=0.04) were 
independent factors influencing patient OS (Fig 2B).  
 
 
Figure 1. Representation of the correlation between PGI activity and tumor size in CRC. Values represent mean ± SE of enzyme activity 
recorded as units of enzyme per milligram of protein (UP/mg prot). Spearman’s rho test: coefficient (r) = -0.248; p< 0.05. 
 
Figure 2. Kaplan-Meier curves and Multivariate Analysis (Cox regression model) with PGI activity in CRC tissues. Overall survival (2A) of 
81 CRC patients according to their tumor PGI activity pattern. Multivariate (2B) analysis of clinicopathological variables and tumor PGI activity in predicting 
overall survival of patients with CRC. 
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Peptidase activity in plasma samples 
compared with controls and according to 
overall survival and other clinicopathological 
variables 
Plasma from CRC patients and healthy individ-
uals showed similar peptidase activities 
(Mann-Whitney test p>0.05) (Table 4). The stratifica-
tion of data according to clinicopathological variables 
also showed no significant changes (Table 1B). 
The analysis of APB activity in plasma samples 
displayed similar results to those obtained in tumor 
tissue. Thus, when plasmatic APB activity was higher 
than 90 UP/L the OS was significantly better in 
Kaplan-Meier curves (Fig 3A) (log-rank p=0.042). 
Multivariate analysis showed that APB activity 
(p=0.03) and local invasion (p=0.02) are independent 
prognostic factors of OS (Fig 3B). 
Discussion 
Many studies have revealed that the altered ex-
pression and activity of several peptidases may play a 
role in tumor transformation and progression of CRC. 
Thus, some authors have proposed that the analysis of 
these enzymes may have a predictive value in the 
early detection and prognosis of patients with CRC 
[10,16,17,31-32]. In this sense, the first studies pointed 
to cell-surface peptidases such as dipep-
tidyl-peptidase IV (DPPIV/CD26) [10], aminopepti-
dase N (APN/CD13) [31] and fibroblast activation 
protein (FAP) [32] as a new tumor markers and 
promising targets for CRC therapy. However, we re-
cently reported that cytosolic peptidases may be also 
of interest in the searching of new markers and targets 
for this disease [16,17]. So, to throw more light to this 
question, in this study we analyzed the activity and 
mRNA expression of three cytosolic enzymes (APB, 
PSA and PGI) in colorectal tissues and plasma from a 
series of CRC patients (see the flow-chart in the Figure 
4). 
 
Table 4. Peptidase activity in plasma from CRC patients. 
Values are means ± SE of units of peptidase per liter of plasma 
(UP/L).  
Peptidase  UP/L (Mean ± S.E )  Mann-Whitney (p =)  
APB    
Patient 95.37 ± 5.34 0.106  
Control  105.29 ± 6.57   
PSA    
Patient 338.07 ± 30.14 0.873  
Control  340.71 ± 48.47   
PGI    
Patient 21.63 ± 3.11 0.988  
Control  18.61 ± 3.29   
 
 
 
Figure 3. Kaplan-Meier curves and Multivariate Analysis (Cox regression model) with APB activity in plasma from CRC patients. 
Overall survival (3A) of 40 CRC patients according to their plasmatic APB activity pattern. Multivariate (3B) analysis of clinicopathological variables and 
tumor APB plasmatic activity in predicting overall survival of patients with CRC. 
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Figure 4. Flow-chart summarizing the most important findings of this study. 
 
The adenoma-adenocarcinoma sequence in the 
large bowel describes that the gradual progression 
from normal to dysplastic epithelium, and hence to 
carcinoma, is associated with the accumulation of 
genetic imbalances [5,6]. It has long been reported that 
expression of several proteases, such as matrix met-
alloproteinases (MMPs) and peptidases, increases 
gradually throughout the sequence, playing an im-
portant role in the development and progression of 
these tumors [33,34]. Furthermore, some studies have 
suggested that the coordinated action of MMPs and 
aminopeptidases is important for the progression of 
several neoplastic diseases [8,35]. In a previous work, 
we observed that PEP activity increased significantly 
in the preneoplastic adenomatous lesions, then stabi-
lizing in adenocarcinomas [18]. In the present study, 
16 adenoma-adenocarcinoma sequences from the 
same patients were analyzed. Spectrofluorimetric 
assay showed that PSA and APB activity was in-
creased significantly in colorectal tumors, but partic-
ularly in the adenomas, where it was two and 
three-fold higher (respectively) than in the adjacent 
uninvolved mucosa. 
On the other hand, the analysis of CRC tissues 
also showed that the activity of PGI correlated nega-
tively with the histological grade and tumor size. 
Moreover, 5-year overall survival of CRC patients was 
significantly better when tissue PGI activity was 
higher. In our previous analysis with ASP and PEP, 
higher tissue activities also correlated with less ag-
gressive forms and with better patient survival 
[16,17]. All this findings taken together suggest that 
the tissue activity of these cytosolic enzymes may be a 
marker of early forms and prognosis of CRC. 
Quantitative RT-PCR assays showed that the 
mRNA levels were not correlated with the enzyme 
activity in colorectal tissues. Thus, (PSA) and (PGI) 
levels were higher in the not cancerous mucosa than 
in CRC and the adenomatous tissues, and mRNA 
levels of RNPEP (APB) did not change significantly 
throughout the adenoma-carcinoma pathway. This 
discrepancy between mRNA and the protein expres-
sion/activity has been described in several studies, 
which could be due to alterations in mRNA transla-
tion efficiency, posttranslational modifications like 
phosphorylation or acethylation, and mRNA and 
protein synthesis and degradation rates [8,22,36-38]. 
Besides, this lack of correlation is widely spread in 
renal diseases involving altered energy metabolism 
like diabetes-induced renal hypertrophy, diabe-
tes-induced matrix synthesis or angiotensin II in-
duced renal injury, and hence, it could be a strong 
possibility for cancer cells to show this discrepancy 
[38-41]. These phenomena illustrate the importance of 
not relying only on mRNA level the evaluation of any 
protein change [38]. 
Topographic distribution of adenocarcinomas 
also displayed significant differences in all the ana-
lyzed peptidases. Thus, rectal carcinomas showed 
decreased enzyme activities compared with colonic 
adenocarcinomas. Recently, we demonstrated a simi-
lar distribution of PEP activity in CRC tissues and 
observed that it was decreased significantly in rectal 
cancer tissues from patients who received 
chemo-radiotherapy preoperatively for a better con-
trol of the disease [17]. Similar patterns were observed 
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with other proteases, which indicate that these en-
zymes could be of potential use in clinical practice to 
predict the response to preoperative 
chemo-radiotherapy [42,43]. We did not observe any 
change in the activity of PSA, APB and PGI in rectal 
cancer in response to preoperative treatment and, 
therefore, further studies are necessary to know the 
cause of these topographic differences. 
Previous studies in a wide variety of tumors 
have demonstrated that cytosolic peptidases may 
change their activities depending on the tumor type 
or on the phase of development where the tumor is. 
For example, it has been reported increased APB, PSA 
and PGI activities in breast [19,20] and thyroid tumors 
[23] with respect to uninvolved tissues. PSA and PGI 
activities were also increased in high grade clear cell 
renal cell carcinomas [22] and higher APB activity was 
correlated with better prognosis of these patients [11]. 
However, these enzymes did not change their activity 
in head and neck cancers [41]. So, these data support 
the idea that tumor growth regulation by peptidases 
occur in a tumor specific manner [8].  
Cytosolic and cell-surface peptidases can be re-
leased to diverse body fluids, including plasma, urine, 
pleural and peritoneal effusions. Although the origin 
of these circulating enzymes is still controversial, the 
comparative studies of peptidase profiles among 
cancer patients and control subjects have yielded sig-
nificant results in several studies [10,17,20,30,45-47]. 
Furthermore, the correlation among plasma/serum 
values and classic histopathological parameters for 
tumor aggressiveness and survival have pointed to 
these enzymes as useful biomarkers for helping in 
screening, diagnosis, staging, prognosis and moni-
toring cancer therapy [10,17-20,30,45-47].  
In this work we did not found any significant 
difference in the analyzed peptidases in plasma be-
tween CRC patients and healthy individuals. How-
ever, higher plasmatic APB activity was inde-
pendently associated with longer patient survival. 
Although this result was opposite of that described 
previously with ASP and PEP, which plasmatic activ-
ities correlated positively with poorer survival rate 
[16,17], these evidences also point to the determina-
tion of cytosolic peptidases in plasma as a valuable 
method in the determination of CRC prognosis. Fur-
ther studies focusing on the molecular translation of 
this descriptive analysis with higher number of pa-
tients would be advisable to confirm the prognostic 
significance of these data. 
Conclusion 
The present study shows for the first time that 
the activity and mRNA levels of PSA, APB and PGI 
are altered throughout the colorectal adeno-
ma-carcinoma sequence and that the activity of tissue 
PGI and plasmatic APB are independent prognostic 
factors for the 5-year survival of CRC patients. Taken 
into account that CRC is a major health problem in 
developed countries, the arrival of cell-surface but 
also cytosolic peptidases as new diagnostic tools with 
prognostic impact may be particularly profitable in 
hospital practice. 
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